Shares of Japanese tech giant Olympus Corp experienced a significant drop on Monday, falling 5.3% on the Tokyo Stock Exchange. This decline follows the announcement that CEO Stefan Kaufmann resigned after allegations surfaced regarding his purchase of illegal drugs.
Olympus swiftly responded to the allegations, consulting with external legal counsel and reporting the matter to investigative authorities. The company fully cooperated with the investigation, which ultimately led the Board of Directors to conclude that Kaufmann’s actions were inconsistent with Olympus’s global code of conduct and core values.
Kaufmann, who had a long tenure of two decades at Olympus, had recently taken the helm to expand the company’s medical equipment division. He stepped down following the allegations, paving the way for former CEO Yasuo Takeuchi to reassume leadership as the search for Kaufmann’s replacement begins.
This incident adds to Olympus’s history of corporate controversies. Notably, in 2011, the company was embroiled in a scandal involving fraudulent accounting practices, revealed by whistleblower and former CEO Michael Woodford.
The resignation of Kaufmann echoes other instances where foreign executives in Japan faced legal troubles due to the country’s stringent drug laws. In 2015, a Toyota executive from the U.S. resigned after being arrested on suspicion of illegally importing painkillers.
Despite the recent turmoil, Olympus shares have seen a 31.9% increase this year, outperforming Japan’s Nikkei 225 index, which rose by 13.3%. As the company navigates this leadership crisis, stakeholders are watching closely to see how it will impact Olympus’s market performance and strategic direction.
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
